235 related articles for article (PubMed ID: 6682193)
1. Treatment of Parkinson's disease with 8-alpha-amino-ergoline, CU 32-085.
Schneider E; Hubener K; Fischer PA
Neurology; 1983 Apr; 33(4):468-72. PubMed ID: 6682193
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant treatment of Parkinson's disease with dopamine agonists: open trial with bromocriptine and CU 32-085.
Jellinger K
J Neurol; 1982; 227(2):75-88. PubMed ID: 6180142
[TBL] [Abstract][Full Text] [Related]
3. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
[TBL] [Abstract][Full Text] [Related]
4. Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide.
Goetz CG; Tanner CM; Glantz RH; Klawans HL
Neurology; 1985 May; 35(5):749-51. PubMed ID: 3990974
[TBL] [Abstract][Full Text] [Related]
5. Clinical experience with cabergoline in patients with advanced Parkinson's disease treated with levodopa.
Marsden CD
Drugs; 1998; 55 Suppl 1():17-22. PubMed ID: 9483166
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic results with a new ergoline derivate (8-alpha-amino-ergoline, CU 32-085) in parkinsonian patients.
Schneider E; Hubener K; Fischer PA
Adv Neurol; 1984; 40():527-9. PubMed ID: 6695631
[No Abstract] [Full Text] [Related]
7. CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease.
Rascol O; Fabre N; Teräväinen H; Poewe W; Lücking C; Rinne U; Dupont E; Hirt D; Hoyer M; Lataste X
Clin Neuropharmacol; 1990 Aug; 13(4):303-11. PubMed ID: 2208182
[TBL] [Abstract][Full Text] [Related]
8. Dopamine agonists as primary treatment in Parkinson's disease.
Rinne UK
Adv Neurol; 1987; 45():519-23. PubMed ID: 3103394
[No Abstract] [Full Text] [Related]
9. Placebo-controlled study of mesulergine in Parkinson's disease.
Jankovic J; Orman J; Jansson B
Neurology; 1985 Feb; 35(2):161-5. PubMed ID: 3881692
[TBL] [Abstract][Full Text] [Related]
10. Dopamine agonists in the treatment of Parkinson's disease.
Rinne UK
Adv Neurol; 1983; 37():141-50. PubMed ID: 6305175
[TBL] [Abstract][Full Text] [Related]
11. Dopamine agonists and Parkinson's disease.
Burton K; Calne DB
Clin Neurol Neurosurg; 1984; 86(3):172-7. PubMed ID: 6091965
[TBL] [Abstract][Full Text] [Related]
12. Treatment of parkinson's disease with bromocriptine.
Lieberman A; Kupersmith M; Estey E; Goldstein M
N Engl J Med; 1976 Dec; 295(25):1400-4. PubMed ID: 989885
[TBL] [Abstract][Full Text] [Related]
13. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
Im JH; Ha JH; Cho IS; Lee MC
J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999
[TBL] [Abstract][Full Text] [Related]
14. Mesulergine (CU 32-085) in the treatment of Parkinson's disease.
Rascol A; Montastruc JL; Rascol O; Senard JM
Clin Neuropharmacol; 1986; 9(2):146-52. PubMed ID: 3708600
[TBL] [Abstract][Full Text] [Related]
15. Three-year observation of mesulergine (CU 32-085) in advanced and newly treated parkinsonism.
Schneider E; Baas H; Fischer PA; Japp G
J Neurol; 1985; 232(1):24-8. PubMed ID: 3998771
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Parkinson's disease with dopamine agonists: a review.
Lieberman A; Neophytides A; Kupersmith M; Casson I; Durso R; Foo SH; Khayali M; Tartaro T; Goldstein M
Am J Med Sci; 1979; 278(1):65-76. PubMed ID: 39452
[TBL] [Abstract][Full Text] [Related]
17. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
Metman LV; Blanchet PJ; de Jong D; Mouradian MM; Chase TN
Mov Disord; 1996 May; 11(3):257-60. PubMed ID: 8723141
[TBL] [Abstract][Full Text] [Related]
18. The use of pergolide, a potent dopamine agonist, in Parkinson's disease.
Lieberman AN; Goldstein M; Neophytides A; Leibowitz M; Gopinathan G; Walker R; Pact V
Clin Pharmacol Ther; 1982 Jul; 32(1):70-5. PubMed ID: 7083733
[TBL] [Abstract][Full Text] [Related]
19. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
Kondo T
J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
[TBL] [Abstract][Full Text] [Related]
20. CQA 206-291 in Parkinson's disease: an acute single escalating dosage study.
Lang AE; Riley DE; Vachon L; Lataste X
Can J Neurol Sci; 1990 Nov; 17(4):416-9. PubMed ID: 2276100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
